SequelSEC

aTYR PHARMA INC ATYR

Biological Products, (No Diagnostic Substances) · CIK 0001339970 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$190.00K
Fiscal year ended 2025-12-31
Operating income
-$77.63M
Fiscal year ended 2025-12-31
Free cash flow
-$62.06M
Fiscal year ended 2025-12-31

aTYR PHARMA INC (ATYR) reported revenue of $190.00K and net income of -$74.12M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from aTYR PHARMA INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

aTYR PHARMA INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$190.00K$235.00K$353.00K$10.39M$0$10.46M$422.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$77.63M-$67.91M-$54.92M-$46.40M-$34.02M-$15.91M-$22.98M
Net income-$74.12M-$64.02M-$50.39M-$45.34M-$33.77M-$16.22M-$16.22M
Research & development$60.22M$54.37M$42.29M$42.81M$23.26M$17.29M$14.05M
Weighted-average diluted sharesshares 92.99Mshares 74.26Mshares 53.61Mshares 28.42Mshares 19.08Mshares 9.16MUnavailable
Pretax income-$74.12M-$64.02M-$50.40M-$45.34M-$33.77M-$16.23M-$23.76M
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$-0.80$-0.86$-0.94$-1.60$-1.77$-1.77Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$17.60M$13.78M$12.98M$13.98M$10.75M$9.08M$9.35M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

aTYR PHARMA INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$10.74M$11.06M$22.54M$9.98M$2.34M$16.95M$9.21M
Total assets$93.00M$96.83M$120.65M$95.79M$115.54M$38.73M$36.19M
Current assets$80.24M$81.95M$102.99M$80.87M$113.57M$35.53M$31.92M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$15.15M$14.97M$16.42M$13.86M$6.01M$5.86M$12.92M
Total equity incl. NCI$67.29M$69.83M$90.47M$71.28M$109.13M$31.48M$21.03M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.89M$4.32M$3.53M$3.11M$1.03M$1.43M$847.00K

Cash flow

aTYR PHARMA INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$61.99M-$69.12M-$33.22M-$41.89M-$33.08M-$15.30M-$20.01M
Capital expenditures$77.00K$65.00K$4.22M$1.64M$192.00K$202.00K$79.00K
Investing cash flow-$5.05M$17.23M-$20.13M$47.24M-$91.57M$6.90M$4.92M
Financing cash flow$66.01M$39.86M$66.23M$5.45M$110.02M$16.14M$1.34M
Net change in cash-$1.03M-$12.02M$12.88M$10.81M-$14.62M$7.74M-$13.75M
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$664.00K$708.00K$592.00K$232.00K$475.00K$569.00K$635.00K

Derived

aTYR PHARMA INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$62.06M-$69.18M-$37.44M-$43.53M-$33.27M-$15.50M-$20.09M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-40856.3%-28899.6%-15557.8%-446.8%Unavailable-152.2%-5445.0%
FCF margin-32664.7%-29440.0%-10605.1%-419.1%Unavailable-148.3%-4761.1%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio5.30x5.48x6.27x5.83x18.89x6.06x2.47x
Revenue YoY growth-19.1%-33.4%-96.6%Unavailable-100.0%2377.5%Unavailable
Net margin-39009.5%-27243.8%-14274.5%-436.5%Unavailable-155.2%Unavailable
R&D / revenue31694.2%23137.0%11981.0%412.2%Unavailable165.4%3328.9%
CapEx / revenue40.5%27.7%1194.1%15.8%Unavailable1.9%18.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATYR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.